Skip to main navigation

Skip Navigation

- Landos - Corp Menu

About Us
- Our Company
- Contact Us
Product Candidates
Science
Investors/Media
Careers
- Why Landos?
- Open Positions

Identifying novel pathways at the interface of immunity and metabolism

Press Releases

Year

9/19/23

Landos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 Congress

9/14/23

Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells

8/9/23

Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results

5/31/23

Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference

5/30/23

Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.

5/25/23

Landos Biopharma Announces 1-for-10 Reverse Stock Split

5/12/23

Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results

3/23/23

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results

2/28/23

Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder

1/11/23

Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12

Investors/Media

Investor Relations

Investor/Media Home
Press Releases
Events & Presentations
Analyst Coverage
Stock Information
SEC Filings
Corporate Governance
Investors/Media FAQs

- Landos - Investor Tools

Print Page
RSS Feeds
Email Alerts

Landos Biopharma, Inc.
PO Box 11239
Blacksburg, VA 24062

info@landosbiopharma.com
(540) 218-2232

- Landos - Footer Menu

Site Map
Terms of Use
Privacy Policy

©2023 Landos Biopharma All Rights Reserved.